Share Email Print

Proceedings Paper

Innovative approaches of clinical photodynamic therapy combined with immunotherapy
Author(s): Zheng Huang
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Photodynamic therapy (PDT) is a clinically approved new treatment modality. It has been used for treatment of non-malignant and malignant diseases. Over the last decade its clinical application has gained increasing acceptance around the world after regulatory approvals. PDT offers various treatment options in cancer management and has been used primarily for localized superficial or endoluminal malignant and premalignant conditions. Recently, its application has also been expanded to solid tumors. However, its efficacy for the treatment of malignant tumors remains debatable and its acceptance still variable. Pre-clinical studies demonstrate that, in addition to the direct local cytotoxicity, PDT can induce host immune responses, which may further enhance the therapeutic effects on primary tumor as well as metastasis. Therefore, PDT-induced antitumor immune response might play an important role in successful control of malignant diseases. Furthermore, the antitumor efficacy of PDT might also be enhanced through an effective immunoadjuvant to further expand its usefulness for a possible control of distant metastases. Recent clinical data also indicate that improved clinical outcomes are seen in the combination of PDT and immunomodulation therapy for non-malignant disease. This review will summarize recent progress in developing innovative approaches of PDT combined with immunotherapy for non-malignant and malignant diseases.

Paper Details

Date Published: 23 February 2006
PDF: 6 pages
Proc. SPIE 6087, Biophotonics and Immune Responses, 608708 (23 February 2006); doi: 10.1117/12.646402
Show Author Affiliations
Zheng Huang, Health Sciences Ctr., Colorado Univ. (United States)

Published in SPIE Proceedings Vol. 6087:
Biophotonics and Immune Responses
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?